Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

Summary The International Initiative on Thrombosis and Cancer is an independent
academic working group of experts aimed at establishing global consensus for the treatment …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Background This is the 2nd update to the 9th edition of these guidelines. We provide
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …

Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …

2.1. 1. Epidemiology and burden of the disease. The annual incidence of first episode of
symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …

Thromboembolism in people with cancer still remains a major health problem and is a
leading cause of mortality after cancer itself, despite being a largely preventable disease. 1 …

PURPOSE To conduct an update of the ASCO venous thromboembolism (VTE) guideline.
METHODS After publication of potentially practice-changing clinical trials, identified through …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐
standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for …